Literature DB >> 2292046

Startle response models of sensorimotor gating and habituation deficits in schizophrenia.

M A Geyer1, N R Swerdlow, R S Mansbach, D L Braff.   

Abstract

Studies of prepulse inhibition and habituation of startle responses elicited by intense stimuli provide some unusual opportunities for cross-species explorations of attentional deficits characteristic of schizophrenic patients. Schizophrenic patients exhibit deficits in both the prepulse inhibition of startle and the habituation of startle. The behavioral plasticity of startle responses and the comparability of the test paradigms used in rats and humans greatly facilitates the development of animal models of specifiable behavioral abnormalities in schizophrenic patients. This review describes two such examples of parallel animal and human models, one involving sensorimotor gating and the other examining behavioral habituation. Evidence is presented supporting the involvement of mesolimbic dopaminergic systems in the modulation of prepulse inhibition or sensorimotor gating and the importance of central serotonergic systems in the habituation of startle.

Entities:  

Mesh:

Year:  1990        PMID: 2292046     DOI: 10.1016/0361-9230(90)90241-q

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  107 in total

1.  Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats.

Authors:  Svetlana Semenova; Daniel Hoyer; Mark A Geyer; Athina Markou
Journal:  Neuropeptides       Date:  2010-10       Impact factor: 3.286

2.  Developmental markers of psychiatric disorders as identified by sensorimotor gating.

Authors:  Susan B. Powell; Mark A. Geyer
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

Review 3.  Gene-environment interplay in schizopsychotic disorders.

Authors:  Tomas Palomo; Trevor Archer; Richard M Kostrzewa; Rrichard J Beninger
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

4.  5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats.

Authors:  R A Padich; T C McCloskey; J H Kehne
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats.

Authors:  J H Kehne; R A Padich; T C McCloskey; V L Taylor; C J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801.

Authors:  D C Hoffman; H Donovan; J V Cassella
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats.

Authors:  K Wedzony; K Gołembiowska; M Zazula
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

8.  D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia.

Authors:  D C Hoffman; H Donovan
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

Review 9.  Behavioral studies of stimulus learning in zebrafish larvae.

Authors:  Ruth M Colwill
Journal:  Behav Processes       Date:  2019-05-02       Impact factor: 1.777

10.  Meclizine enhancement of sensorimotor gating in healthy male subjects with high startle responses and low prepulse inhibition.

Authors:  José A Larrauri; Lisalynn D Kelley; Mason R Jenkins; Eric C Westman; Nestor A Schmajuk; M Zachary Rosenthal; Edward D Levin
Journal:  Neuropsychopharmacology       Date:  2013-09-18       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.